Agilon Health price target raised to $28 from $22 at Wells Fargo

Wells Fargo analyst Stephen Baxter raised the firm’s price target on Agilon Health to $28 from $22 and keeps an Overweight rating on the shares. Commentary on 2024 expectations was better-than-feared, given the potential headwinds from proposed MA rates and risk model changes, the firm notes.